The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology
Open accessAbstract
Blood proteins and their complexes have become the focus of a great deal of interest in the context of their potential as biomarkers of Alzheimer's disease (AD). We used a SOMAscan assay for quantifying 1001 proteins in blood samples from 331 AD, 211 controls, and 149 mild cognitive impaired (MCI) subjects. The strongest associations of protein levels with AD outcomes were prostate‐specific antigen complexed to α1‐antichymotrypsin (AD diagnosis), pancreatic prohormone (AD diagnosis, left entorhinal cortex atrophy, and left hippocampus atrophy), clusterin (rate of cognitive decline), and fetuin B (left entorhinal atrophy). Multivariate analysis found that a subset of 13 proteins predicted AD with an accuracy of area under the curve of 0.70. Our replication of previous findings provides further evidence that levels of these proteins in plasma are truly associated with AD. The newly identified proteins could be potential biomarkers and are worthy of further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“novel and highly sensitive high‐throughput protein arrays, such as aptamer‐based technologies, immunobased proximity extension assays, or antibody suspension beads arrays, which can readily measure large sets of protein libraries in CSF and blood samples. 132 , 133 , 134 , 135 , 136 , 137 , 138”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [132]
In the citing paper
“The coverage of proteins on the platform has taken into account proteins known to be relevant to human disease, including neurodegenerative diseases55 and cardiovascular diseases56; thus it has been widely used for biomarker discovery.”
From Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders (2021) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754 · cited 1×
“[22].”
Self-citationInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048
CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000046581.81650.d0 · Cited by 621 · cited 2×
“Similarly, positron emission tomography imaging of amyloid burden in the brain correlates with clinical diagnosis of AD, Ab neuropathology at autopsy [3,4,6], and CSFAb1-42 levels [7–10] but is equally impractical for use in large groups of frail elderly patients and is restricted to specialist centers.”
Shi, F., Liu, B., Zhou, Y., Yu, C., & Jiang, T. (2009) · Hippocampus · doi:10.1002/hipo.20573 · Cited by 470
Proteome-based plasma biomarkers for Alzheimer's disease
Hye, A., Lynham, S., Thambisetty, M., Čaušević, M., Campbell, J., Byers, H. L., Hooper, C., Rijsdijk, F. V., Tabrizi, S. J., Banner, S. J., et al. (2006) · Brain · doi:10.1093/brain/awl279 · Cited by 461 · cited 2×
“All subjects were assessed with a standardized assessment protocol including an informant interview for diagnosis and cognitive assessment such as the Mini-Mental State Examination (MMSE) together with standardized assessment of function, behavior, and dementia severity as previously reported [13,19,20].”
Self-citationRelationships between biomarkers in aging and dementia
Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., Foster, N. L., Petersen, R. C., Weiner, M. W., Price, J. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc010c · Cited by 456
Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease
Doecke, J. D. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1282 · Cited by 422
Thambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., Wahlund, L.-O., Westman, E., Kinsey, A., Güntert, A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.78 · Cited by 405 · cited 2×
“This finding replicates pervious findings, which showed the association of clusterin with more severe disease and rapid clinical progression [20,35].”
Self-citationShen, L., Kim, S., Risacher, S. L., Nho, K. T., Swaminathan, S., West, J. D., Foroud, T., Pankratz, N., Moore, J. H., Sloan, C., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.01.042 · Cited by 383
Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357
Denecke, B., Gräber, S., Schäfer, C., Heiss, A., Wöltje, M., & Jahnen‐Dechent, W. (2003) · Biochemical Journal · doi:10.1042/bj20030676 · Cited by 291
Grimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278 · cited 1×
“Similarly, positron emission tomography imaging of amyloid burden in the brain correlates with clinical diagnosis of AD, Ab neuropathology at autopsy [3,4,6], and CSFAb1-42 levels [7–10] but is equally impractical for use in large groups of frail elderly patients and is restricted to specialist centers.”
Chronic Psychological Distress and Risk of Alzheimer’s Disease in Old Age
Wilson, R. S., Arnold, S. E., Schneider, J. A., Kelly, J. F., Tang, Y., & Bennett, D. A. (2006) · Neuroepidemiology · doi:10.1159/000095761 · Cited by 266 · cited 1×
“The rate of cognitive decline (disease progression) in 329 AD patients (214 from ANM, 87 from ARUK, and 28 from DCR) was calculated based on longitudinal MMSE assessments [26].”
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease
Hu, W. T., Holtzman, D. M., Fagan, A. M., Shaw, L. M. J., Perrin, R. J., Arnold, S. E., Grossman, M., Xiong, C., Craig‐Schapiro, R., Clark, C. M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318266fa70 · Cited by 237
A Serum Protein–Based Algorithm for the Detection of Alzheimer Disease
O’Bryant, S. E. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.215 · Cited by 230
Plasma clusterin and the risk of Alzheimer disease
Schrijvers, E. M. C. (2011) · JAMA · doi:10.1001/jama.2011.381 · Cited by 220 · cited 1×
“This finding replicates pervious findings, which showed the association of clusterin with more severe disease and rapid clinical progression [20,35].”
Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease
Soares, H. D. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1070 · Cited by 218
Westman, E., Aguilar, C., Muehlboeck, J., & Simmons, A. (2012) · Brain Topography · doi:10.1007/s10548-012-0246-x · Cited by 214
Self-citationAddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease
Lovestone, S., Francis, P. T., Kłoszewska, I., Mecocci, P., Simmons, A., Soininen, H. S., Spenger, C., Tsolaki, M., Vellas, B. J., Wahlund, L., et al. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05064.x · Cited by 211 · cited 1×
“Of these subjects, 415 (110 controls, 66 MCI patients, 43 MCI patients converting to AD, and 196 AD patients) were recruited from the European Union–funded AddNeuroMed (ANM) biomarker study [14,21] and 276 subjects (101 controls, 40 MCI, and 135 AD) were recruited from the Maudsley and King’s Healthcare Partners Demen…”
Self-citationIdentification of oxidized plasma proteins in Alzheimer's disease
Choi, J., Malakowsky, C. A., Talent, J. M., Conrad, C. C., & Gracy, R. W. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00420-5 · Cited by 181 · cited 1×
“a1Antitrypsin has been found to be associated with AD [36,44–46] and brain amyloid burden [39].”
Mining biomarkers in human sera using proteomic tools
Zhang, R., Barker, L. T., Pinchev, D., Marshall, J. G., Rasamoelisolo, M., Smith, C. R., Kupchak, P., Kireeva, I., Ingratta, L., & Jackowski, G. (2004) · PROTEOMICS · doi:10.1002/pmic.200300495 · Cited by 179
Wolf, H., Grunwald, M., Kruggel, F., Riedel-Heller, S. G., Angerhöfer, S., Hojjatoleslami, A., Hensel, A., Arendt, T., & Gertz, H.-J. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00238-4 · Cited by 164 · cited 1×
“Changes to the hippocampal right-to-left asymmetry were alluded by previous studies [51–53].”
Relationship of Cerebrospinal Fluid Markers to11C-PiB and18F-FDDNP Binding
Tolboom, N., van der Flier, W. M., Yaqub, M. M., Boellaard, R., Verwey, N. A., Blankenstein, M. A., Windhorst, A. D., Scheltens, P., Lammertsma, A. A., & van Berckel, B. N. M. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.064360 · Cited by 161 · cited 1×
“Similarly, positron emission tomography imaging of amyloid burden in the brain correlates with clinical diagnosis of AD, Ab neuropathology at autopsy [3,4,6], and CSFAb1-42 levels [7–10] but is equally impractical for use in large groups of frail elderly patients and is restricted to specialist centers.”
Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum
Schneider, P., Hampel, H. J., & Büerger, K. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00104.x · Cited by 154 · cited 1×
“Although AD is a disease of the brain, it is increasingly accepted that there is communication between the brain and the periphery, and thus several studies, including those from our own group, have investigated AD and/or MCIrelated protein changes in blood plasma using mass spectrometry and antibody capture technolog…”
Abraham, C. R., Shirahama, T., & Potter, H. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90045-2 · Cited by 150
α1‐Antichymotrypsin as a possible biochemical marker for Alzheimer‐type dementia
Matsubara, E., Hirai, S., Amari, M., Shoji, M., Yamaguchi, H., Okamoto, K., Ishiguro, K., Harigaya, Y., & Wakabayashi, K. (1990) · Annals of Neurology · doi:10.1002/ana.410280414 · Cited by 146 · cited 1×
“a1-Antichymotrypsin colocalizes with amyloid plaques in AD brain [27] and both prostatespecific antigen [28,29] and a1-antichymotrypsin [30,31] are detectable in CSF.”
Agrin Is a Major Heparan Sulfate Proteoglycan Accumulating in Alzheimer's Disease Brain
Verbeek, M. M., Otte‐Höller, I., van den Born, J., van den Heuvel, L. P. W. J., David, G., Wesseling, P., & de Waal, R. M. W. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65529-0 · Cited by 141 · cited 1×
“Other proteins generally linked to AD pathology in the literature that we also found to be altered in the periphery include glypican 3, higher levels of which were found in AD patients, individuals with high left and right hippocampal atrophy, and MCI patients converting to AD within 1 year; glypican 1 was previously…”
Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease
Björkqvist, M., Ohlsson, M., Minthon, L., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029868 · Cited by 135 · cited 1×
“[50] quantified the same 18 proteins in plasma from 174 controls, 142 patients with AD, and 88 patients with other dementias and found that these 18 proteins could classify patients with AD from controls only with low diagnostic precision (AUC 5 0.”
Hertze, J., Minthon, L., Zetterberg, H., Vanmechelen, E., Blennow, K., & Hansson, O. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100207 · Cited by 135 · cited 1×
“These measurements together not only differentiate AD from normal elderly controls with high accuracy but can also predict which subjects with mild cognitive impairment (MCI) are likely to progress to AD within 5 years [5].”
Simmons, A., Westman, E., Muehlboeck, S., Mecocci, P., Vellas, B. J., Tsolaki, M., Kłoszewska, I., Wahlund, L., Soininen, H. S., Lovestone, S., et al. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2491 · Cited by 134 · cited 1×
“Detailed information regarding data acquisition, preprocessing, and quality control assessment has been described for this cohort elsewhere [24,25].”
Self-citationGlycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease
Hye, A., Kerr, F., Archer, N. J., Foy, C., Poppe, M., Brown, R. G., Hamilton, G., Powell, J. F., Anderton, B. H., & Lovestone, S. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.10.031 · Cited by 130 · cited 1×
“Although AD is a disease of the brain, it is increasingly accepted that there is communication between the brain and the periphery, and thus several studies, including those from our own group, have investigated AD and/or MCIrelated protein changes in blood plasma using mass spectrometry and antibody capture technolog…”
Self-citationMRI Measures of Alzheimer's Disease and the AddNeuroMed Study
Simmons, A., Westman, E., Muehlboeck, S., Mecocci, P., Vellas, B. J., Tsolaki, M., Kłoszewska, I., Wahlund, L., Soininen, H. S., Lovestone, S., et al. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05063.x · Cited by 128
Self-citationBarnes, J., Scahill, R. I., Schott, J. M., Frost, C. D., Rossor, M. N., & Fox, N. C. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000084560 · Cited by 108 · cited 1×
“Changes to the hippocampal right-to-left asymmetry were alluded by previous studies [51–53].”
CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease
Schoonenboom, N. S. M., van der Flier, W. M., Blankenstein, M. A., Bouwman, F. H., van Kamp, G. J., Barkhof, F., & Scheltens, P. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.018 · Cited by 107 · cited 1×
“Similarly, positron emission tomography imaging of amyloid burden in the brain correlates with clinical diagnosis of AD, Ab neuropathology at autopsy [3,4,6], and CSFAb1-42 levels [7–10] but is equally impractical for use in large groups of frail elderly patients and is restricted to specialist centers.”
Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden
Kiddle, S. J., Thambisetty, M., Simmons, A., Riddoch-Contreras, J., Hye, A., Westman, E., Pike, I., Ward, M., Johnston, C., Lupton, M. K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044260 · Cited by 100
Self-citationA Blood-Based Algorithm for the Detection of Alzheimer’s Disease
O’Bryant, S. E., Xiao, G., Barber, R. C., Reisch, J., Hall, J. R., Cullum, C. M., Doody, R. S., Fairchild, T., Adams, P. M., Wilhelmsen, K. C., et al. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000330750 · Cited by 96
Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma
Yu, H., Chertkow, H. M., Bergman, H., & Schipper, H. M. (2003) · PROTEOMICS · doi:10.1002/pmic.200300475 · Cited by 95 · cited 1×
“a1Antitrypsin has been found to be associated with AD [36,44–46] and brain amyloid burden [39].”
Hoe, H.-S., Cooper, M. J., Burns, M. P., Lewis, P. A., van der Brug, M., Chakraborty, G., Cartagena, C. M., Pak, D. T. S., Cookson, M. R., & Rebeck, G. W. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3135-07.2007 · Cited by 90 · cited 1×
“We found that levels of metalloproteinase inhibitor 3, which has previously been shown to be increased in AD brains [43], was significantly increased in the plasma of AD patients with a fast rate of cognitive decline.”
Thambisetty, M., Hye, A., Foy, C., Daly, E., Glover, A., Cooper, A., Simmons, A., Murphy, D., & Lovestone, S. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0006-8 · Cited by 84 · cited 1×
“All subjects were assessed with a standardized assessment protocol including an informant interview for diagnosis and cognitive assessment such as the Mini-Mental State Examination (MMSE) together with standardized assessment of function, behavior, and dementia severity as previously reported [13,19,20].”
Self-citationLicastro, F., Parnetti, L., Morini, M. C., Davis, L. J., Cucinotta, D., GAITI, A., & Senin, U. (1995) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199509020-00009 · Cited by 84
Biomarkers for disease modification trials--the innovative medicines initiative and AddNeuroMed.
Lovestone, S., Francis, P. T., & Strandgaard, K. (2007) · PubMed · Cited by 72
Self-citationSerum Levels of Pregnancy Zone Protein are Elevated in Presymptomatic Alzheimer’s Disease
IJsselstijn, L., Dekker, L. J. M., Stingl, C., van der Weiden, M. M., Albert Hofman, D., Kros, J. M., Koudstaal, P. J., Smitt, P. A. E. S., Ikram, M. A., Breteler, M. M. B., et al. (2011) · Journal of Proteome Research · doi:10.1021/pr200270z · Cited by 62 · cited 1×
“Other proteins that we were able to replicate include apolipoprotein E [19,37–39,47], granulocyte colony–stimulating factor [15,18], matrix metallopeptidase 9 [36,39], fibronectin [48], complement component C6 [49], and immunoglobulin E [39].”
Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease
Liao, P., Yu, L., Kuo, C., Lin, C., & Kuo, Y. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200600684 · Cited by 55 · cited 1×
“a1Antitrypsin has been found to be associated with AD [36,44–46] and brain amyloid burden [39].”
Henkel, A. W., Müller, K., Lewczuk, P., Müller, T., Marcus, K., Kornhuber, J., & Wiltfang, J. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0781-3 · Cited by 42 · cited 1×
“Other proteins that we were able to replicate include apolipoprotein E [19,37–39,47], granulocyte colony–stimulating factor [15,18], matrix metallopeptidase 9 [36,39], fibronectin [48], complement component C6 [49], and immunoglobulin E [39].”
Smith, E. R., Nilforooshan, R., Weaving, G., & Tabet, N. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-101872 · Cited by 40
Büerger, K., Ernst, A. S., Ewers, M., Uspenskaya, O., Omerovic, M., Morgenthaler, N. G., Knauer, K., Bergmann, A., & Hampel, H. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.032 · Cited by 38
Alzheimers Disease, Ceramide, Visfatin and NAD
Adams, J. D., Jr. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708787122969 · Cited by 26
Prostate-Specific Antigen in Cerebrospinal Fluid
Melegos, D. N., Freedman, M. S., & Diamandis, E. P. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.5.855 · Cited by 17 · cited 1×
“a1-Antichymotrypsin colocalizes with amyloid plaques in AD brain [27] and both prostatespecific antigen [28,29] and a1-antichymotrypsin [30,31] are detectable in CSF.”
Biomarkers for Alzheimer's disease trials — biomarkers for what? A discussion paper
Lovestone, S., & Thambisetty, M. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0033-x · Cited by 15 · cited 1×
“016 Open access under CC BY-NC-ND of the disease, will be essential to the development of drugs for early intervention [1].”
Self-citationFuriak, N. M., Klein, R. W., Kahle‐Wrobleski, K., Siemers, E., Sarpong, E., & Klein, T. M. (2010) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-10-24 · Cited by 14 · cited 1×
“Additionally, if sufficiently powered and inexpensive, a biomarker could potentially be used as part of a screening program for at-risk elderly people [2].”
CSF levels of PSA and PSA–ACT complexes in Alzheimer's disease
Mulder, S. D., Heijst, J. A., Mulder, C., Martens, F., Hack, C. E., Scheltens, P., Blankenstein, M. A., & Veerhuis, R. (2009) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2009.009130 · Cited by 11 · cited 1×
“[32] found that prostate-specific antigen was present in the brain, but levels of prostate-specific antigen and PSA-ACT complex did not differ across in CSF samples from controls, frontotemporal lobe dementia, and AD and MCI patients.”
Prostate-Specific Antigen Immunoreactivity in Spinal Fluid
Wolff, J. M., Borchers, H., Kunitz, O., Planz, B., & Jakse, G. (2010) · Urologia Internationalis · doi:10.1159/000283070 · Cited by 5 · cited 1×
“a1-Antichymotrypsin colocalizes with amyloid plaques in AD brain [27] and both prostatespecific antigen [28,29] and a1-antichymotrypsin [30,31] are detectable in CSF.”
Cited by
Sorted by citations
Genomic atlas of the human plasma proteome
Sun, B. B., Maranville, J. C., Peters, J. E., Stacey, D., Staley, J. R., Blackshaw, J., Burgess, S., Jiang, T., Paige, E., Surendran, P., et al. (2018) · Nature · doi:10.1038/s41586-018-0175-2 · Cited by 2,268
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Ageing, neurodegeneration and brain rejuvenation
Wyss-Coray, T. (2016) · Nature · doi:10.1038/nature20411 · Cited by 1,147
Undulating changes in human plasma proteome profiles across the lifespan
Lehallier, B., Gate, D., Schaum, N., Nanasi, T., Lee, S. E., Yousef, H., Moran Losada, P., Berdnik, D., Keller, A., Verghese, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0673-2 · Cited by 981
Connecting genetic risk to disease end points through the human blood plasma proteome
Suhre, K., Arnold, M., Bhagwat, A. M., Cotton, R. J., Engelke, R., Raffler, J., Sarwath, H., Thareja, G., Wahl, A., DeLisle, R. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14357 · Cited by 800
Metadata
- Authors
- Sattlecker, M., Kiddle, S. J., Newhouse, S., Proitsi, P., Nelson, S., Williams, S., Johnston, C., Killick, R., Simmons, A., Westman, E., Hodges, A., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., AddNeuroMed Consortium, & Dobson, R. J. B.
- Affiliations
- King's College London (GB)
- SomaLogic (United States) (US)
- University of Eastern Finland (FI)
- Medical University of Lodz (PL)
- University of Perugia (IT)
- Aristotle University of Thessaloniki (GR)
- Inserm (FR)
- Corresponding author
- Dobson, Richard J.B.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2014-04-28
- Volume
- 10
- Issue
- 6
- Pages
- 724-734
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2035892094
- Cited by
- 223
- References
- 54
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 19 · 2023: 15 · 2022: 13 · 2021: 26 · 2020: 22 · 2019: 16 · 2018: 18 · 2017: 13 · 2016: 20 · 2015: 26 · 2014: 9
- FWCI
- 17.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Portal (King's College London) (acceptedVersion, cc-by-nc-nd)
- UCL Discovery (University College London) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Funders
- NIHR Newcastle Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, biomarkers
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Atrophy, Blood Proteins, Brain, Female, Humans, Magnetic Resonance Imaging, Male, ROC Curve, Cohort Studies, Biomarkers, Logistic Models, Proteomics, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
